Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:ABT
- CUSIP: 00282410
- Web: www.abbott.com
Capitalization:- Market Cap: $77.58 billion
- Outstanding Shares: 1,735,272,000
Average Prices:- 50 Day Moving Avg: $43.77
- 200 Day Moving Avg: $42.22
- 52 Week Range: $36.76 - $45.84
P/E:- Trailing P/E Ratio: 46.52
- Foreward P/E Ratio: 16.20
- P/E Growth: 1.59
Sales & Book Value:- Annual Revenue: $22.3 billion
- Price / Sales: 3.48
- Book Value: $18.07 per share
- Price / Book: 2.47
Dividend:- Annual Dividend: $1.06
- Dividend Yield: 2.4%
Profitability:- EBIDTA: $4.77 billion
- Net Margins: 6.71%
- Return on Equity: 15.74%
- Return on Assets: 8.27%
Debt:- Debt-to-Equity Ratio: 0.29%
- Current Ratio: 1.56%
- Quick Ratio: 1.25%
Misc:- Average Volume: 6.55 million shs.
- Beta: 0.97
- Short Ratio: 2.01
Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Friday, February 17th. Stockholders of record on Friday, April 14th will be given a dividend of $0.265 per share on Monday, May 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date is Tuesday, April 11th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) released its earnings results on Wednesday, April, 19th. The company reported $0.48 EPS for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.05. The business earned $6.34 billion during the quarter, compared to the consensus estimate of $6.16 billion. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. The business's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.41 EPS. View Abbott Laboratories' Earnings History.
When will Abbott Laboratories make its next earnings announcement?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories updated its FY17 earnings guidance on Wednesday, April, 19th. The company provided earnings per share guidance of $2.40-2.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.45.
Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?
14 equities research analysts have issued 1 year price objectives for Abbott Laboratories' shares. Their forecasts range from $42.00 to $55.00. On average, they expect Abbott Laboratories' share price to reach $48.64 in the next twelve months. View Analyst Ratings for Abbott Laboratories.
What are analysts saying about Abbott Laboratories stock?
Here are some recent quotes from research analysts about Abbott Laboratories stock:
- 1. According to Zacks Investment Research, "For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters." (5/26/2017)
- 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Medtronic plc. (MDT), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG), Zimmer Biomet Holdings (ZBH), Edwards Lifesciences Corp (EW), Smith & Nephew plc (SNN), Hologic (HOLX), Align Technology (ALGN), ResMed (RMD), Varian Medical Systems (VAR), Steris PLC (STE), ABIOMED (ABMD), Masimo (MASI), NuVasive (NUVA), Globus Medical (GMED), Wright Medical Group (WMGI) and Nevro Corp (NVRO).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Miles D. White, Chairman of the Board, Chief Executive Officer
- Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
- Michael T. Rousseau, President - Cardiovascular and Neuromodulation
- Hubert L. Allen, Executive Vice President, General Counsel, Secretary
- Stephen R. Fussell, Executive Vice President - Human Resources
- Brian J. Blaser, Executive Vice President - Diagnostics Products
- John M. Capek Ph.D., Executive Vice President - Ventures
- Robert B. Ford, Executive Vice President - Medical Devices
- Heather L. Mason, Executive Vice President - Nutritional Products
- Roger Bird, Senior Vice President - U.S. Nutrition
Who owns Abbott Laboratories stock?
Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.64%), Massachusetts Financial Services Co. MA (0.00%), Wellington Management Group LLP (0.00%) and Bank of New York Mellon Corp (1.96%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?
Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Flossbach Von Storch AG, Pzena Investment Management LLC, FMR LLC, SG Americas Securities LLC, Macquarie Group Ltd., APG Asset Management N.V., Camber Capital Management LLC and Bahl & Gaynor Inc.. Company insiders that have sold Abbott Laboratories stock in the last year include Brian B Yoor, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?
Abbott Laboratories' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Wellington Management Group LLP, Massachusetts Financial Services Co. MA, State Street Corp, Boston Partners, Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy Abbott Laboratories stock?
Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of Abbott Laboratories stock can currently be purchased for approximately $44.71.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Abbott Laboratories (NYSE:ABT)Earnings History by Quarter for Abbott Laboratories (NYSE ABT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/18/2017 | | | | | | | | |
| 4/19/2017 | 3/31/2017 | $0.43 | $0.48 | $6.16 billion | $6.34 billion | View | N/A |  |
| 1/25/2017 | Q416 | $0.64 | $0.65 | $5.41 billion | $5.33 billion | View | Listen | |
| 10/19/2016 | Q316 | $0.58 | $0.59 | $5.29 billion | $5.30 billion | View | Listen | |
| 7/20/2016 | Q216 | $0.53 | $0.55 | $5.24 billion | $5.30 billion | View | Listen | |
| 4/20/2016 | Q116 | $0.39 | $0.41 | $4.77 billion | $4.90 billion | View | Listen | |
| 1/28/2016 | Q415 | $0.61 | $0.62 | $5.31 billion | $5.20 billion | View | Listen | |
| 10/21/2015 | Q315 | $0.53 | $0.54 | $5.16 billion | $5.15 billion | View | Listen | |
| 7/22/2015 | Q215 | $0.50 | $0.52 | $5.15 billion | $5.20 billion | View | Listen | |
| 4/22/2015 | Q115 | $0.42 | $0.47 | $4.85 billion | $4.90 billion | View | Listen | |
| 1/29/2015 | Q414 | $0.68 | $0.71 | $5.48 billion | $5.36 billion | View | Listen | |
| 10/22/2014 | Q314 | $0.60 | $0.62 | $5.62 billion | $5.10 billion | View | Listen | |
| 7/16/2014 | Q214 | $0.51 | $0.54 | $5.53 billion | $5.55 billion | View | Listen | |
| 4/16/2014 | Q114 | $0.36 | $0.41 | $5.29 billion | $5.24 billion | View | Listen | |
| 1/22/2014 | Q413 | $0.58 | $0.58 | $5.72 billion | $5.66 billion | View | Listen | |
| 10/16/2013 | Q313 | $0.52 | $0.55 | $5.46 billion | $5.37 billion | View | Listen | |
| 7/17/2013 | Q2 2013 | $0.44 | $0.46 | $5.53 billion | $5.45 billion | View | Listen | |
| 4/17/2013 | Q1 2013 | $0.41 | $0.42 | $5.42 billion | $5.38 billion | View | Listen | |
| 1/23/2013 | Q4 2012 | $1.50 | $1.51 | $10.58 billion | $10.80 billion | View | Listen | |
| 10/17/2012 | | $1.28 | $1.30 | | | View | N/A | |
| 7/18/2012 | | $1.22 | $1.23 | | | View | N/A | |
| 4/18/2012 | | $1.00 | $1.03 | | | View | N/A | |
| 1/25/2012 | | $1.44 | $1.45 | | | View | N/A | |
| 10/19/2011 | | $1.17 | $1.18 | | | View | N/A | |
| 7/20/2011 | | $1.12 | $1.12 | | | View | N/A | |
| 4/20/2011 | | $0.90 | $0.91 | | | View | N/A | |
| 1/26/2011 | | $1.29 | $1.30 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Abbott Laboratories (NYSE:ABT)2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.85
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.43 | $0.50 | $0.45 |
| Q2 2017 | 2 | $0.60 | $0.61 | $0.61 |
| Q3 2017 | 2 | $0.64 | $0.68 | $0.66 |
| Q4 2017 | 2 | $0.72 | $0.73 | $0.73 |
| Q1 2018 | 1 | $0.56 | $0.56 | $0.56 |
| Q2 2018 | 1 | $0.71 | $0.71 | $0.71 |
| Q3 2018 | 1 | $0.74 | $0.74 | $0.74 |
| Q4 2018 | 1 | $0.84 | $0.84 | $0.84 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Abbott Laboratories (NYSE:ABT)| Most Recent Dividend: | 5/15/2017 |
| Annual Dividend: | $1.06 |
| Dividend Yield: | 2.37% |
| Dividend Growth: | 22.90% (3 Year Average) |
| Payout Ratio: | 113.98% (Trailing 12 Months of Earnings)
42.91% (Based on This Year's Estimates)
38.41% (Based on Next Year's Estimates)
|
| Track Record: | 44 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Abbott Laboratories (NYSE ABT)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/17/2017 | quarterly | $0.27 | 2.36% | 4/11/2017 | 4/14/2017 | 5/15/2017 |
| 12/9/2016 | quarterly | $0.27 | 2.7% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/15/2016 | quarterly | $0.26 | 2.48% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/10/2016 | quarterly | $0.26 | 2.75% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.26 | 2.66% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 12/11/2015 | quarterly | $0.26 | 2.32% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/17/2015 | quarterly | $0.24 | 2.22% | 10/13/2015 | 10/15/2015 | 11/15/2015 |
| 6/12/2015 | quarterly | $0.24 | 2% | 7/13/2015 | 7/15/2015 | 8/15/2015 |
| 2/20/2015 | quarterly | $0.24 | 2.03% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 12/12/2014 | quarterly | $0.24 | 2.21% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/11/2014 | quarterly | $0.22 | 2.07% | 10/10/2014 | 10/15/2014 | 11/15/2014 |
| 6/13/2014 | quarterly | $0.22 | 2.21% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/21/2014 | quarterly | $0.22 | 2.26% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 10/16/2013 | quarterly | $0.22 | 2.37% | 1/13/2014 | 1/15/2014 | 2/15/2014 |
| 9/12/2013 | quarterly | $0.14 | 1.61% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/14/2013 | quarterly | $0.14 | 1.52% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.14 | 1.61% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 12/14/2012 | quarterly | $0.14 | 0.86% | 1/11/2013 | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)Insider Ownership Percentage: 0.26%
Institutional Ownership Percentage: 62.20%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/27/2017 | Roger Bird | Insider | Sell | 5,600 | $43.82 | $245,392.00 | |
| 4/26/2017 | Joseph J Manning | Insider | Sell | 4,200 | $43.95 | $184,590.00 | |
| 3/1/2017 | Michael J. Warmuth | Insider | Sell | 3,851 | $45.39 | $174,796.89 | |
| 2/23/2017 | Robert E Funck | VP | Sell | 25,500 | $45.50 | $1,160,250.00 | |
| 2/22/2017 | Roger Bird | Insider | Sell | 13,222 | $45.02 | $595,254.44 | |
| 2/21/2017 | Deepak S Nath | Insider | Sell | 319 | $44.98 | $14,348.62 | |
| 1/31/2017 | Heather L Mason | Insider | Sell | 35,700 | $40.77 | $1,455,489.00 | |
| 12/20/2016 | Brian J Blaser | Insider | Buy | 15,580 | $38.45 | $599,051.00 | |
| 12/14/2016 | Robert B Ford | Insider | Buy | 12,775 | $39.09 | $499,374.75 | |
| 11/10/2016 | Miles D White | Chairman | Buy | 121,456 | $40.45 | $4,912,895.20 | |
| 11/1/2016 | Sally E Blount | Director | Buy | 5,100 | $39.24 | $200,124.00 | |
| 9/26/2016 | Daniel Gesua Sive Salvadori | SVP | Sell | 815 | $41.71 | $33,993.65 | |
| 7/28/2016 | Stephen R Fussell | Insider | Sell | 41,500 | $45.00 | $1,867,500.00 | |
| 7/26/2016 | Michael J Warmuth | Insider | Sell | 26,800 | $43.49 | $1,165,532.00 | |
| 7/25/2016 | Miles D White | Chairman | Buy | 242,547 | $43.18 | $10,473,179.46 | |
| 7/25/2016 | Robert E Funck | VP | Sell | 26,800 | $43.08 | $1,154,544.00 | |
| 6/28/2016 | Hubert L Allen | EVP | Sell | 3,400 | $37.14 | $126,276.00 | |
| 6/15/2016 | Jared Watkin | SVP | Sell | 552 | $37.63 | $20,771.76 | |
| 6/1/2016 | Brian B Yoor | CFO | Sell | 565 | $39.49 | $22,311.85 | |
| 4/28/2016 | Deepak S Nath | SVP | Sell | 53 | $41.31 | $2,189.43 | |
| 3/31/2016 | Jaime Contreras | SVP | Sell | 462 | $41.78 | $19,302.36 | |
| 2/29/2016 | Brian B Yoor | CFO | Sell | 865 | $39.12 | $33,838.80 | |
| 2/29/2016 | Deepak S Nath | SVP | Sell | 793 | $39.27 | $31,141.11 | |
| 2/29/2016 | Robert B Ford | EVP | Sell | 1,706 | $39.28 | $67,011.68 | |
| 2/29/2016 | Robert E Funck | VP | Sell | 1,333 | $39.30 | $52,386.90 | |
| 2/22/2016 | Jared Watkin | SVP | Sell | 554 | $39.09 | $21,655.86 | |
| 2/16/2016 | Deepak S. Nath | SVP | Sell | 171 | $37.13 | $6,349.23 | |
| 12/16/2015 | Miles D. White | CEO | Sell | 438,000 | $46.00 | $20,148,000.00 | |
| 8/18/2015 | Stephen R. Fussell | EVP | Sell | 13,096 | $50.46 | $660,824.16 | |
| 4/27/2015 | Heather L Mason | EVP | Sell | 13,500 | $47.45 | $640,575.00 | |
| 4/27/2015 | Roger Bird | SVP | Sell | 28,548 | $47.57 | $1,358,028.36 | |
| 3/26/2015 | J. Scott White | SVP | Sell | 12,483 | $46.68 | $582,706.44 | |
| 3/2/2015 | Jaime Contreras | SVP | Sell | 9,209 | $47.34 | $435,954.06 | |
| 2/4/2015 | John M Capek | EVP | Sell | 34,292 | $45.66 | $1,565,772.72 | |
| 11/25/2014 | Jaime Contreras | SVP | Sell | 51,600 | $44.07 | $2,274,012.00 | |
| 10/29/2014 | Miles D White | CEO | Sell | 440,800 | $42.52 | $18,742,816.00 | |
| 3/3/2014 | John Landgraf | EVP | Sell | 17,293 | $39.38 | $680,998.34 | |
| 3/3/2014 | Katherine Doyle | SVP | Sell | 6,639 | $39.01 | $258,987.39 | |
| 3/3/2014 | Robert Funck | VP | Sell | 1,413 | $38.97 | $55,064.61 | |
| 2/18/2014 | John Landgraf | EVP | Sell | 1,583 | $39.10 | $61,895.30 | |
| 1/29/2014 | Michael Warmuth | EVP | Sell | 11,430 | $36.21 | $413,880.30 | |
| 12/6/2013 | Jean-Yves Pavee | SVP | Sell | 5,855 | $37.46 | $219,328.30 | |
| 11/7/2013 | Stephen Fussell | EVP | Sell | 10,466 | $37.59 | $393,416.94 | |
| 10/30/2013 | Jaime Contreras | SVP | Sell | 25,368 | $36.85 | $934,810.80 | |
| 6/7/2013 | Heather L Mason | SVP | Sell | 12,000 | $37.01 | $444,120.00 | |
| 2/1/2013 | William A Osborn | Director | Buy | 10,000 | $33.86 | $338,600.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
| Source: |
|
| Date | Headline |
|---|
 | Global Markets May Drive Established Pharmaceuticals Growth
finance.yahoo.com - May 29 at 3:17 PM |
| Abbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : May 29, 2017
finance.yahoo.com - May 29 at 3:17 PM |
| Emerging Markets Drive Abbott’s Nutritional Business Growth
finance.yahoo.com - May 26 at 3:15 PM |
| Abbott Continues to Expand Its Diagnostics Portfolio in 2017
finance.yahoo.com - May 26 at 3:15 PM |
| Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others
finance.yahoo.com - May 26 at 3:15 PM |
 | Abbott Laboratories (ABT) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 26 at 10:59 AM |
| How Will Abbott Laboratories Benefit from Its Alere Acquisition?
finance.yahoo.com - May 25 at 8:32 PM |
| The Zacks Analyst Blog Highlights: Alphabet, Morgan Stanley, Abbott, Waste Management, General Mills and Raytheon
finance.yahoo.com - May 25 at 3:30 PM |
| Is Medical Technology Driving the US Healthcare Industry?
finance.yahoo.com - May 25 at 3:30 PM |
 | FDA: Controller for heart pump recalled over deaths
marketbeat.com - May 24 at 6:29 PM |
| Abbott Laboratories (ABT) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 24 at 9:04 AM |
| Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna
finance.yahoo.com - May 24 at 5:17 AM |
 | Abbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - May 22 at 3:15 PM |
| Abbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - May 22 at 3:15 PM |
| Abbott Laboratories (ABT) Downgraded by TheStreet
www.americanbankingnews.com - May 21 at 10:34 PM |
 | New Div On The Block Quarterly Earnings Round-Up: Part 2
seekingalpha.com - May 21 at 1:19 AM |
| VTV, ABT, MDLZ, AET: Large Outflows Detected at ETF
www.nasdaq.com - May 18 at 12:36 PM |
| Goldman Sachs Group Inc Initiates Coverage on Abbott Laboratories (ABT)
www.americanbankingnews.com - May 16 at 8:56 PM |
 | Former Angels, Orioles star convicted of insider trading
www.bizjournals.com - May 16 at 8:18 PM |
 | Goldman Starts Abbott Laboratories at 'Neutral' - TheStreet.com
www.thestreet.com - May 16 at 3:17 PM |
 | Goldman Sachs Starts Abbott Labs (ABT) at Neutral - StreetInsider.com
www.streetinsider.com - May 16 at 3:17 PM |
| Goldman Starts Abbott Laboratories at 'Neutral'
finance.yahoo.com - May 16 at 3:17 PM |
| Abbott Laboratories (ABT) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - May 16 at 10:57 AM |
| Abbott Laboratories (ABT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 15 at 9:42 AM |
| Retired baseball player DeCinces found guilty of insider trading
finance.yahoo.com - May 12 at 8:30 PM |
| Abbott Laboratories' (ABT) Buy Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - May 12 at 7:46 AM |
| IYY, AGN, ABT, MDLZ: Large Outflows Detected at ETF
www.nasdaq.com - May 11 at 12:03 AM |
| Abbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
finance.yahoo.com - May 9 at 9:31 AM |
| Buying A Very Safe Dividend
seekingalpha.com - May 8 at 8:17 PM |
| Abbott Laboratories – Value Analysis (NYSE:ABT) : May 8, 2017
finance.yahoo.com - May 8 at 8:17 PM |
| Abbott Announces National Reimbursement for FreeStyle® Libre in France, Providing Access to Revolutionary Technology for People with Diabetes
finance.yahoo.com - May 8 at 11:29 AM |
| Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor
finance.yahoo.com - May 8 at 11:29 AM |
| Analysts Expect Abbott Laboratories (ABT) Will Post Quarterly Sales of $6.63 Billion
www.americanbankingnews.com - May 7 at 7:54 AM |
| Abbott's Interesting Quarter - Seeking Alpha
seekingalpha.com - May 6 at 3:27 PM |
| Abbott Laboratories (ABT) Expected to Post Earnings of $0.60 Per Share
www.americanbankingnews.com - May 5 at 8:24 PM |
| Abbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : May 5, 2017
finance.yahoo.com - May 5 at 3:17 PM |
| Analysis Of AbbVie's Pipeline: What's Left Of Abbott's Biopharma Growth Opportunities?
seekingalpha.com - May 4 at 3:16 PM |
| Abbott Laboratories (ABT) Given Daily News Sentiment Score of 0.09
www.americanbankingnews.com - May 2 at 7:48 AM |
| Alere, set to be acquired by Abbott, dealt setback in Medicare case
finance.yahoo.com - May 1 at 3:17 PM |
| Abbott Laboratories (ABT) Given Daily Media Impact Rating of 0.18
www.americanbankingnews.com - April 29 at 8:42 AM |
| Joseph J. Manning Sells 4,200 Shares of Abbott Laboratories (ABT) Stock
www.americanbankingnews.com - April 29 at 1:09 AM |
| Abbott Laboratories (ABT) Insider Sells $245,392.00 in Stock
www.americanbankingnews.com - April 29 at 1:09 AM |
| Abbott launches nutrition drinks for surgery patients - Seeking Alpha
seekingalpha.com - April 26 at 3:25 PM |
| Abbott Introduces Science-Based Nutrition Drinks to Help Patients Have a Better Recovery from Surgery
finance.yahoo.com - April 26 at 3:25 PM |
| Abbott Laboratories (ABT) Getting Somewhat Negative Media Coverage, Analysis Shows
www.americanbankingnews.com - April 26 at 9:18 AM |
| Global Market For Medical Implants To Hit Nearly $27 Billion In 5 Years
finance.yahoo.com - April 26 at 5:54 AM |
| Abbott's First Quarter: Medical Device Segment Grows Over 100%
seekingalpha.com - April 25 at 3:17 PM |
| Cramer's lightning round: Nobody ever made money betting against this CEO
finance.yahoo.com - April 25 at 6:37 AM |
| Abbott Laboratories: Constantly Adapting For Enduring Success
seekingalpha.com - April 24 at 11:18 AM |
| Q3 2017 EPS Estimates for Abbott Laboratories Cut by Leerink Swann (ABT)
www.americanbankingnews.com - April 24 at 8:44 AM |
Abbott Laboratories (ABT) Chart for Monday, May, 29, 2017
